Table 3.

Re-treatment^* of Study Eyes by Category of Type 1 ROP at Enrollment

	Zone I, any Stage with Plus Disease	Zone I, Stage 3 without Plus Disease	Zone II, Stage 2 or 3 with Plus Disease	All Eyes
Enrolled & Treated	19	8	34	61
Re-treated for early failure	0 (0%)	1 (13%)	2 (6%)	3 (5%)
Re-treated for late recurrence of ROP	4 (21%)	2 (25%)	5 (15%)	11 (18%)
Re-treated for persistent avascular retina	3 (16%)	1 (13%)	7 (21%)	11 (18%)
No additional treatment	12 (63%)	4 (50%)	20 (59%)	36 (59%)

^*Re-treatment included photoablative therapy or intravitreal bevacizumab at investigator discretion.